Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Lifted by Wallace Advisory Group LLC

Wallace Advisory Group LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 55.5% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,021 shares of the medical research company’s stock after acquiring an additional 1,078 shares during the quarter. Thermo Fisher Scientific makes up 1.2% of Wallace Advisory Group LLC’s holdings, making the stock its 17th largest holding. Wallace Advisory Group LLC’s holdings in Thermo Fisher Scientific were worth $1,671,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Accretive Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 8.1% during the 4th quarter. Accretive Wealth Partners LLC now owns 640 shares of the medical research company’s stock valued at $340,000 after purchasing an additional 48 shares during the period. Aveo Capital Partners LLC boosted its position in Thermo Fisher Scientific by 9.7% during the 4th quarter. Aveo Capital Partners LLC now owns 816 shares of the medical research company’s stock worth $433,000 after acquiring an additional 72 shares during the period. Gryphon Financial Partners LLC lifted its position in shares of Thermo Fisher Scientific by 8.5% in the fourth quarter. Gryphon Financial Partners LLC now owns 1,484 shares of the medical research company’s stock worth $794,000 after purchasing an additional 116 shares in the last quarter. Carolinas Wealth Consulting LLC grew its position in Thermo Fisher Scientific by 30.4% during the fourth quarter. Carolinas Wealth Consulting LLC now owns 365 shares of the medical research company’s stock valued at $194,000 after purchasing an additional 85 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $382,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, VP Lisa P. Britt sold 3,624 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the transaction, the vice president now directly owns 13,699 shares of the company’s stock, valued at approximately $8,397,760.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. The disclosure for this sale can be found here. Insiders have sold a total of 23,084 shares of company stock valued at $14,094,292 over the last three months. 0.34% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on TMO. Wells Fargo & Company assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price target on the stock. Barclays lowered their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. Bank of America raised their price target on Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. JPMorgan Chase & Co. boosted their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Finally, Robert W. Baird raised their price objective on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $650.41.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $614.42 on Monday. The stock has a 50-day simple moving average of $606.08 and a 200 day simple moving average of $581.88. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $627.88. The stock has a market capitalization of $234.53 billion, a PE ratio of 39.41, a P/E/G ratio of 3.88 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same period in the prior year, the business earned $5.15 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was down 1.4% compared to the same quarter last year. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.